NCT03890302View on ClinicalTrials.gov

Evaluate the Safety, Tolerability, Pharmacokinetics,and Clinical Activity of FB704A

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

March 14, 2019

Primary Completion Date

May 27, 2020

Study Completion Date

May 27, 2020

Conditions
Rheumatoid Arthritis
Interventions
DRUG

FB704A

Administered by IV infusion

DRUG

Placebo

Identical in appearance and same excipients as FB704A, but without active compound. Administered by IV infusion

Trial Locations (1)

66212

Altasciences Clinical Kansas, Inc., Overland Park

Sponsors

Collaborators (1)

Oneness Biotech Co., Ltd.
All Listed Sponsors
collaborator

Oneness Biotech Co., Ltd.

INDUSTRY

lead

Fountain Biopharma Inc.

INDUSTRY

NCT03890302 - Evaluate the Safety, Tolerability, Pharmacokinetics,and Clinical Activity of FB704A | Biotech Hunter | Biotech Hunter